The ₹230-crore IPO of Fabtech Applied sciences has opened for public subscription beginning in the present day.
At 10.57 am on Day 1, the IPO acquired 0.07 occasions subscription, with non-institutional buyers (NIIs) bidding 0.08 occasions and the retail class at 0.17 occasions. QIBs have been nil on the time of writing.
The IPO concludes on October 1, 2025.
IPO particulars
The turnkey engineering options supplier for pharma and healthcare trade has fastened a worth band of ₹181-191 per share for its IPO, a contemporary concern of as much as 1.2 crore fairness shares value ₹230 crore on the higher finish of the worth band. The minimal lot dimension is 75 shares and multiples thereof.
The Mumbai-based firm will use the proceeds to fund working capital necessities, pursuing inorganic development initiatives via acquisitions and common company functions.
Unistone Capital is the only real book-running lead supervisor to the problem.
Brokerage view
The IPO has not bagged a robust ‘subscribe’ score from brokerages. Reliance Securities famous that Fabtech’s asset-light mannequin, proprietary mission administration system and presence in rising markets make it well-positioned to capitalise on the structural development in world pharmaceutical capital expenditure. The corporate’s diversified order e book additionally lends visibility to near-term revenues.
Nonetheless, the brokerage flagged dangers resembling low proposal-to-order conversion charges and reliance on third-party procurement.
Quoting that the corporate is pretty valued, Reliance Securities assigned a impartial score to the problem.
Revealed on September 29, 2025